The detection of psilocybin, the psychoactive compound in certain mushrooms, through standard drug screening methods is relatively uncommon. Most routine drug tests, such as those used by employers or for legal purposes, are designed to identify substances like opioids, amphetamines, cocaine, and marijuana. These panels rarely include specific assays for psilocybin or its metabolite, psilocin.
This stems from a combination of factors including the relatively short period during which psilocybin is detectable in the body and the perceived lower prevalence of its use compared to other controlled substances. Furthermore, the cost associated with adding psilocybin testing to standard panels may outweigh the perceived benefits for many testing programs. Historically, drug testing initiatives have focused on substances with a greater impact on workplace safety and public health, leading to a prioritization of other drugs.